SPOTLIGHT: BMS cool to prospect of Sanofi merger

Bristol-Myers Squibb prefers to grow on its own steam, thank you: Financial sources say the company's not interested in merging with Sanofi-Aventis. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik.